FDA Delays Impacting Inflammatory Skin Disease Community

Video

Mark Lebwohl, MD, explains the recent delay in approval of JAK inhibitors by the FDA, how it is affecting the inflammatory skin disease community, and if physicians should be concerned.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.